Drug Trial Radar · NCT06036836
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Sep 29, 2023
Primary completion
Mar 12, 2026
Study completion Mar 12, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) \[Cohort A\] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) \[Cohort B\].
Conditions
- Solid Tumor
- Cutaneous Squamous Cell Carcinoma
- Endometrial Cancer
Interventions
favezelimab/pembrolizumabBiological
IV infusion
pembrolizumabBiological
IV infusion
lenvatinibDrug
Oral administration of capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Rate - Cohort ATime frame: Up to approximately 22 months
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Investigator - Cohort BTime frame: Up to approximately 21 months
Locations
44 sites in 10 countries. Site status is shown where the registry gives one.
Yale-New Haven Hospital-Yale Cancer Center ( Site 0643)
New Haven, Connecticut
Dana-Farber Cancer Institute ( Site 0642)
Boston, Massachusetts
Rutgers Cancer Institute of New Jersey ( Site 0635)
New Brunswick, New Jersey
Duke Cancer Institute ( Site 0641)
Durham, North Carolina
Cleveland Clinic Main ( Site 0639)
Cleveland, Ohio
St. Luke's University Health Network ( Site 0636)
Bethlehem, Pennsylvania
UPMC Hillman Cancer Center ( Site 0644)
Pittsburgh, Pennsylvania
UT Southwestern Medical Center-CRO-Simmons Comprehensive Cancer Center ( Site 0645)
Dallas, Texas
St Vincent's Hospital-The Kinghorn Cancer Centre ( Site 0005)
Darlinghurst, New South Wales, Australia
Royal North Shore Hospital ( Site 0008)
St Leonards, New South Wales, Australia
Blacktown Hospital ( Site 0003)
Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 0002)
Brisbane, Queensland, Australia
The Alfred Hospital ( Site 0004)
Melbourne, Victoria, Australia
Fiona Stanley Hospital ( Site 0006)
Murdock, Western Australia, Australia
Sunnybrook Research Institute ( Site 0607)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0606)
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal ( Site 0602)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0605)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0604)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Québec, Quebec, Canada
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0155)
Paris, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0153)
Strasbourg, Alsace, France
CENTRE LEON BERARD ( Site 0151)
Lyon Cedex08, Auvergne-Rhône-Alpes, France
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 0154)
Brest, Finistere, France
Universitaetsklinikum Essen ( Site 0185)
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0182)
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0183)
Dresden, Saxony, Germany
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi
Naples, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-SC Oncologia Medica 3 - Tumori Testa-collo ( Site 025
Milan, Lombardy, Italy
Hospital Sultan Ismail-Pusat Rawatan Radioterapi Dan Onkologi ( Site 0063)
Johor Bahru, Johor, Malaysia
University Malaya Medical Centre ( Site 0061)
Lembah Pantai, Kuala Lumpur, Malaysia
Sarawak General Hospital-Radiotherapy Unit ( Site 0062)
Kuching, Sarawak, Malaysia
University Medical Center Groningen ( Site 0273)
Groningen, Netherlands
Radboudumc ( Site 0274)
Nijmegen, Gelderland, Netherlands
Erasmus Medisch Centrum ( Site 0272)
Rotterdam, South Holland, Netherlands
Taichung Veterans General Hospital-GYNECOLOGY ( Site 0033)
Taichung, Taiwan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0032)
Tainan, Taiwan
National Taiwan University Hospital ( Site 0031)
Taipei, Taiwan
Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 0424)
Ankara, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0421)
Ankara, Turkey (Türkiye)
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.